Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
CYH vs THC vs HCA vs UHS vs SGRY
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
CYH vs THC vs HCA vs UHS vs SGRY — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $408M | $17.01B | $95.95B | $10.68B | $1.87B |
| Revenue (TTM) | $21.48B | $21.45B | $75.60B | $17.76B | $3.34B |
| Net Income (TTM) | $-88M | $1.70B | $6.78B | $1.52B | $-76M |
| Gross Margin | 53.7% | 42.8% | 41.5% | 67.6% | 22.8% |
| Operating Margin | -39.8% | 16.1% | 15.8% | 11.5% | 11.8% |
| Forward P/E | 0.8x | 10.9x | 14.2x | 7.3x | 38.0x |
| Total Debt | $11.58B | $13.17B | $50.20B | $5.51B | $4.02B |
| Cash & Equiv. | $260M | $2.88B | $1.04B | $138M | $240M |
CYH vs THC vs HCA vs UHS vs SGRY — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Community Health Sy… (CYH) | 100 | 91.9 | -8.1% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
| Universal Health Se… (UHS) | 100 | 161.7 | +61.7% |
| Surgery Partners, I… (SGRY) | 100 | 106.8 | +6.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CYH vs THC vs HCA vs UHS vs SGRY
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CYH is the #2 pick in this set and the best alternative if value is your priority.
- Lower P/E (0.8x vs 38.0x)
THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- +27.4% vs SGRY's -38.2%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 9.0% margin vs SGRY's -2.3%
- Beta 0.29 vs CYH's 1.60
UHS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 9.7%, EPS growth 37.3%, 3Y rev CAGR 9.0%
- Lower volatility, beta 0.60, Low D/E 74.3%, current ratio 1.05x
- 9.7% revenue growth vs CYH's -1.2%
Among these 5 stocks, SGRY doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.7% revenue growth vs CYH's -1.2% | |
| Value | Lower P/E (0.8x vs 38.0x) | |
| Quality / Margins | 9.0% margin vs SGRY's -2.3% | |
| Stability / Safety | Beta 0.29 vs CYH's 1.60 | |
| Dividends | 0.7% yield, 5-year raise streak, vs UHS's 0.5%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +27.4% vs SGRY's -38.2% | |
| Efficiency (ROA) | 11.3% ROA vs SGRY's -0.9%, ROIC 19.9% vs 4.1% |
CYH vs THC vs HCA vs UHS vs SGRY — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CYH vs THC vs HCA vs UHS vs SGRY — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 2 of 6 categories
HCA leads 2 • CYH leads 0 • UHS leads 0 • SGRY leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 22.6x SGRY's $3.3B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to SGRY's -2.3%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $21.5B | $21.5B | $75.6B | $17.8B | $3.3B |
| EBITDAEarnings before interest/tax | -$7.8B | $4.3B | $15.5B | $2.7B | $572M |
| Net IncomeAfter-tax profit | -$88M | $1.7B | $6.8B | $1.5B | -$76M |
| Free Cash FlowCash after capex | -$200M | $3.3B | $7.7B | $894M | $208M |
| Gross MarginGross profit ÷ Revenue | +53.7% | +42.8% | +41.5% | +67.6% | +22.8% |
| Operating MarginEBIT ÷ Revenue | -39.8% | +16.1% | +15.8% | +11.5% | +11.8% |
| Net MarginNet income ÷ Revenue | -0.4% | +7.9% | +9.0% | +8.6% | -2.3% |
| FCF MarginFCF ÷ Revenue | -0.9% | +15.6% | +10.2% | +5.0% | +6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.8% | +2.8% | +6.7% | +9.6% | +4.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -45.2% | +87.6% | +44.6% | +17.7% | +6.7% |
Valuation Metrics
Evenly matched — CYH and UHS and SGRY each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 0.8x trailing earnings, CYH trades at a 95% valuation discount to HCA's 15.1x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $408M | $17.0B | $95.9B | $10.7B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $11.7B | $27.3B | $145.1B | $16.0B | $5.7B |
| Trailing P/EPrice ÷ TTM EPS | 0.77x | 12.53x | 15.12x | 7.38x | -23.46x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.94x | 14.19x | 7.30x | 37.99x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.38x | 0.72x | 0.46x | — |
| EV / EBITDAEnterprise value multiple | — | 6.34x | 9.37x | 6.14x | 10.00x |
| Price / SalesMarket cap ÷ Revenue | 0.03x | 0.80x | 1.27x | 0.61x | 0.57x |
| Price / BookPrice ÷ Book value/share | — | 1.97x | — | 1.48x | 0.52x |
| Price / FCFMarket cap ÷ FCF | 1.96x | 6.72x | 12.47x | 12.57x | 9.57x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-2 for SGRY. UHS carries lower financial leverage with a 0.74x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), THC scores 7/9 vs SGRY's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +19.6% | — | +20.7% | -2.2% |
| ROA (TTM)Return on assets | -0.7% | +5.7% | +11.3% | +9.8% | -0.9% |
| ROICReturn on invested capital | -70.1% | +13.2% | +19.9% | +12.3% | +4.1% |
| ROCEReturn on capital employed | -87.3% | +13.8% | +27.0% | +16.0% | +5.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 7 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 1.47x | — | 0.74x | 1.14x |
| Net DebtTotal debt minus cash | $11.3B | $10.3B | $49.2B | $5.4B | $3.8B |
| Cash & Equiv.Liquid assets | $260M | $2.9B | $1.0B | $138M | $240M |
| Total DebtShort + long-term debt | $11.6B | $13.2B | $50.2B | $5.5B | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 4.89x | 4.28x | 5.37x | 10.92x | 1.35x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $1,902 for CYH. Over the past 12 months, THC leads with a +27.4% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs SGRY's -25.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -6.6% | -2.7% | -8.6% | -22.3% | -6.2% |
| 1-Year ReturnPast 12 months | -11.7% | +27.4% | +19.7% | -8.2% | -38.2% |
| 3-Year ReturnCumulative with dividends | -16.8% | +178.5% | +57.4% | +20.8% | -59.2% |
| 5-Year ReturnCumulative with dividends | -81.0% | +190.4% | +109.7% | +12.5% | -72.3% |
| 10-Year ReturnCumulative with dividends | -80.3% | +523.4% | +450.5% | +30.8% | -0.6% |
| CAGR (3Y)Annualised 3-year return | -6.0% | +40.7% | +16.3% | +6.5% | -25.8% |
Risk & Volatility
Evenly matched — THC and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than CYH's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 78.5% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.60x | 0.71x | 0.29x | 0.60x | 1.04x |
| 52-Week HighHighest price in past year | $4.47 | $247.21 | $556.52 | $246.33 | $24.18 |
| 52-Week LowLowest price in past year | $2.38 | $146.60 | $330.00 | $152.33 | $11.41 |
| % of 52W HighCurrent price vs 52-week peak | +64.8% | +78.5% | +77.1% | +69.2% | +59.2% |
| RSI (14)Momentum oscillator 0–100 | 46.4 | 52.9 | 30.8 | 39.7 | 63.3 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 1.2M | 1000K | 793K | 1.5M |
Analyst Outlook
HCA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CYH as "Hold", THC as "Buy", HCA as "Buy", UHS as "Hold", SGRY as "Buy". Consensus price targets imply 38.1% upside for THC (target: $268) vs 1.2% for CYH (target: $3). For income investors, HCA offers the higher dividend yield at 0.69% vs UHS's 0.47%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $2.93 | $268.00 | $527.45 | $231.50 | $18.60 |
| # AnalystsCovering analysts | 37 | 32 | 46 | 43 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | +0.5% | — |
| Dividend StreakConsecutive years of raises | 2 | 0 | 5 | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | $2.94 | $0.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | +8.4% | +10.5% | +9.1% | 0.0% |
THC leads in 2 of 6 categories (Income & Cash Flow, Total Returns). HCA leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
CYH vs THC vs HCA vs UHS vs SGRY: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CYH or THC or HCA or UHS or SGRY a better buy right now?
For growth investors, Universal Health Services, Inc.
(UHS) is the stronger pick with 9. 7% revenue growth year-over-year, versus -1. 2% for Community Health Systems, Inc. (CYH). Community Health Systems, Inc. (CYH) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate Tenet Healthcare Corporation (THC) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CYH or THC or HCA or UHS or SGRY?
On trailing P/E, Community Health Systems, Inc.
(CYH) is the cheapest at 0. 8x versus HCA Healthcare, Inc. at 15. 1x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CYH or THC or HCA or UHS or SGRY?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -81. 0% for Community Health Systems, Inc. (CYH). Over 10 years, the gap is even starker: THC returned +523. 4% versus CYH's -80. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CYH or THC or HCA or UHS or SGRY?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Community Health Systems, Inc. 's 1. 60β — meaning CYH is approximately 460% more volatile than HCA relative to the S&P 500. On balance sheet safety, Universal Health Services, Inc. (UHS) carries a lower debt/equity ratio of 74% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CYH or THC or HCA or UHS or SGRY?
By revenue growth (latest reported year), Universal Health Services, Inc.
(UHS) is pulling ahead at 9. 7% versus -1. 2% for Community Health Systems, Inc. (CYH). On earnings-per-share growth, the picture is similar: Community Health Systems, Inc. grew EPS 196. 7% year-over-year, compared to -52. 6% for Tenet Healthcare Corporation. Over a 3-year CAGR, SGRY leads at 9. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CYH or THC or HCA or UHS or SGRY?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus -2. 4% for Surgery Partners, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -79. 4% for CYH. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CYH or THC or HCA or UHS or SGRY more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 38. 0x for Surgery Partners, Inc. — 30. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 38. 1% to $268. 00.
08Which pays a better dividend — CYH or THC or HCA or UHS or SGRY?
In this comparison, HCA (0.
7% yield), UHS (0. 5% yield) pay a dividend. CYH, THC, SGRY do not pay a meaningful dividend and should not be held primarily for income.
09Is CYH or THC or HCA or UHS or SGRY better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Community Health Systems, Inc. (CYH) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCA: +450. 5%, CYH: -80. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CYH and THC and HCA and UHS and SGRY?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CYH is a small-cap deep-value stock; THC is a mid-cap deep-value stock; HCA is a mid-cap deep-value stock; UHS is a mid-cap deep-value stock; SGRY is a small-cap quality compounder stock. HCA pays a dividend while CYH, THC, UHS, SGRY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.